More Data Support Trodelvy-Keytruda Combo in Triple-Negative Breast Cancer

‘Critically important’: Upfront sacituzumab govitecan combo benefits breast cancer subset

CHICAGO — New findings from the randomized phase 3 ASCENT-04 trial reinforce prior research that first-line sacituzumab govitecan plus pembrolizumab should be “standard of care” for PD-L1-positive metastatic…